This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. M. WINTROBE, M.D.; G. E. CARTWRIGHT, M.D.

AMA Arch Intern Med. 1956;98(5):559-566.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The Problem

In 1922, Werner Schultz¹ described a syndrome which ultimately came to be known as agranulocytosis. At first but a few cases were recognized, but between 1929 and 1934 a large number were reported. About this time (1931) Kracke² noted that the sudden appearance and growing number of cases of agranulocytosis corresponded with the introduction of certain coal-tar derivatives as therapeutic agents. The disorder was especially common in the countries in which such drugs were in great use, and those affected were chiefly women of good economic status as well as nurses and other medical workers to whom these drugs were easily accessible. Shortly afterward several reports appeared* which incriminated aminopyrine (Pyramidon) as the offending drug. After 1934 the number of cases of agranulocytosis began to decrease. This coincided with the reduced sales of aminopyrine following reports of its injurious effects.⁵

Later, however, as new drugs . . . [Full Text PDF of this Article]

Author Affiliations
Salt Lake City

From the Department of Medicine, University of Utah College of Medicine.

Footnotes
Submitted for publication June 29, 1956.

Read in the Symposium on Hematology of the Joint Meeting of the Section on Experimental Medicine and Therapeutics and the Section on Internal Medicine at the 105th Annual Meeting of the American Medical Association, Chicago, June 14, 1956.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?